))
Ep 29 | The Intersection Between the Inflation Reduction Act (IRA) & 340B – Conversation with Jeff Davis
Manage episode 378014771 series 3374171
A tartalmat a SpendMend Pharmacy biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a SpendMend Pharmacy vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
In this episode, Greg and Rob are joined by healthcare attorney Jeff Davis, to discuss how the Medicare drug pricing provisions in the IRA will impact 340B providers. They’ll go over CMS billing modifier requirements (15:27), share opinions on the financial impact covered entities might experience (38:02), and how various legal challenges to the IRA by the pharma industry may play out (56:29). They also add some insights around CMS’s proposed Part B payment remedy (1:01:03).
In the intro, Rob catches Greg up on new manufacturer restrictions, and some recent HRSA audit experience related to interpreting data request list (DRL) revisions, and shares some commentary on the current House E&C subcommittee hearing on proposed drug shortage legislation.
Email us questions, thoughts, and ideas for podcast topics at 340BUnscripted@spendmend.com!
62 epizódok
Megosztás
